KOSDAQHolding Companies084110

Huons Global

₩19,120▲ 0.79%2026-11-18 close
Market Cap
₩242.1B
Turnover
₩300M
Volume
20K
Shares out.
12.7M
PER
12.7×
PBR
0.4×
EPS
₩1,477
Dividend Yield
4.67%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩880 per share · Prices as of the 2026-11-18 close

01

Report overview

Subsidiary growth diverges from a loss-making core unit

Huons Global's third-quarter 2026 revenue rose 1.7% year on year, but operating profit fell 53.9%, with the loss-making core subsidiary Huons as the main drag.

  1. 1

    Revenue grew for three straight years from 2023 through 2025, while operating profit peaked at KRW 113.9 billion in 2023 and declined for two consecutive years from 2024.

  2. 2

    Third-quarter 2026 revenue was KRW 214.8 billion and operating profit was KRW 9.39 billion, down 53.9% year on year.

  3. 3

    Subsidiary Huons swung to a preliminary operating loss of KRW 4.5 billion in the third quarter of 2026, while the aesthetics unit Humedix and the health-supplement unit posted revenue growth.

  4. 4

    After a parent-attributable net loss of KRW 777 million in the second quarter of 2026, the third quarter returned to a KRW 6.23 billion profit, and the last four quarters total KRW 18 billion.

  5. 5

    The third-quarter dividend has a record date of December 4, 2026 and a scheduled payment date of December 22, 2026, and the next periodic report is the 2026 annual report.

02

Business structure

Huons Global is the holding company of the Huons group, holding stakes in several subsidiaries across pharmaceuticals, aesthetics, health supplements and healthcare materials.

The core operating subsidiary Huons (243070) relies on a vaccine business launched this year and its domestic pharmaceutical franchise, both of which the company said kept growing.

However, the end of the continuous glucose monitor business and the absence of US exports pushed Huons' preliminary third-quarter 2026 revenue to KRW 144 billion, down 6.3% year on year.

The aesthetics subsidiary Humedix reported third-quarter 2026 revenue of KRW 50.2 billion and operating profit of KRW 10 billion, up 22.8% and 11.3% year on year, supported by wider domestic supply of aesthetic products and new ophthalmic eye-drop orders.

The health-supplement unit booked KRW 21.8 billion in revenue, helped by the merger with Biorojet and growth in OEM and exports. The healthcare-materials unit recorded KRW 15 billion in revenue, combining KRW 9 billion from glass products and KRW 6 billion from cosmetics.

The botulinum toxin unit posted KRW 10.4 billion in revenue, up 32.8% from the prior quarter, after receiving Chinese product approval and beginning initial shipments earlier this year. Overseas expansion proceeds through country-by-country registration and approvals, followed by sales territories and partnerships.

Peers in the pharmaceutical holding segment, such as Hanmi Science, offer a reference point, and group results are best read as the sum of individual subsidiary performance.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩211.2B₩20.3B9.6%
2025Q4₩224.5B₩19.4B8.6%
2026Q1₩197B₩9.2B4.7%
2026Q2₩214.1B₩19.5B9.1%
2026Q3₩214.8B₩9.4B4.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩664.4B₩86.5B-₩60.3B13.0%−13.0%58.2%
2023₩758.4B₩113.9B₩38.4B15.0%7.6%44.7%
2024₩813.5B₩97B₩25.8B11.9%5.0%45.8%
2025₩847.5B₩90.6B₩28.8B10.7%5.3%43.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On an annual basis, revenue rose from KRW 664.4 billion in 2022 to KRW 758.4 billion in 2023 (up 14.2% year on year), KRW 813.5 billion in 2024 (up 7.3%) and KRW 847.5 billion in 2025 (up 4.2%), growing for three consecutive years from 2023 through 2025, with 2025 the largest year of 2022 through 2025.

Operating profit climbed from KRW 86.5 billion in 2022 to KRW 113.9 billion in 2023 (up 31.8%), then fell to KRW 97 billion in 2024 (down 14.9%) and KRW 90.6 billion in 2025 (down 6.6%), declining for two consecutive years from 2024 through 2025.

The operating margin moved from 13.0% in 2022 and 15.0% in 2023 down to 11.9% in 2024 and 10.7% in 2025, so revenue expanded while margins compressed.

Profit attributable to owners of the parent swung from a net loss of KRW 60.3 billion in 2022 to a profit of KRW 38.4 billion in 2023, fell to KRW 25.8 billion in 2024 (down 32.8%), and recovered to KRW 28.8 billion in 2025 (up 11.8%).

Total net income, which includes non-controlling interests, was a loss of KRW 33.5 billion in 2022, then KRW 92.6 billion, KRW 67.1 billion and KRW 81.8 billion in 2023 through 2025, and the gap with parent-attributable profit reflects the non-controlling share.

The debt-to-equity ratio fell from 58.2% in 2022 to 43.0% in 2025, with total equity of KRW 1.09 trillion at end-2025, of which KRW 546.7 billion belongs to parent shareholders, and total liabilities of KRW 468.7 billion.

Operating cash flow was KRW 64.4 billion in 2022, KRW 100 billion in 2023, KRW 100.6 billion in 2024 and KRW 93.6 billion in 2025, staying above KRW 90 billion each year from 2023.

Quarterly revenue went from KRW 211.2 billion in the third quarter of 2025 and KRW 224.5 billion in the fourth quarter (up 6.3% quarter on quarter) to KRW 197 billion in the first quarter of 2026 (down 12.3%), then rose to KRW 214.1 billion in the second quarter (up 8.7%) and KRW 214.8 billion in the third quarter (up 0.3% quarter on quarter and 1.7% year on year), growing for two consecutive quarters from the second quarter of 2026.

Quarterly operating profit was KRW 20.3 billion, KRW 19.4 billion, KRW 9.16 billion (down 52.8%), KRW 19.5 billion (up 112.9%) and KRW 9.39 billion (down 51.9%) across the five quarters, with the third quarter down 53.9% year on year.

Subsidiary Huons attributed its preliminary third-quarter operating loss to higher R&D spending, cost increases and recall costs on a US-exported product.

Parent-attributable net income swung to a loss of KRW 777 million in the second quarter of 2026 and returned to KRW 6.23 billion in the third quarter, though that figure fell 42.2% year on year, and the operating profit and parent-level profit moved in different directions in the second quarter, so non-operating items and non-controlling allocations need to be checked in the periodic report notes.

05

Industry analysis

Within the pharmaceutical holding framework, Huons Global combines manufacturing and regulatory-driven drug businesses with aesthetics, health supplements and materials units.

Compared with pharmaceutical holding peers such as Hanmi Science, the mix of business segments and subsidiaries is the main factor separating their earnings trajectories.

In the drug segment, the vaccine business launched in 2026 is still at the stage of establishing a market position, which the company presented as a task for expanding its revenue base.

The domestic pharmaceutical franchise grew, but the absence of US exports and recall costs on exported products weighed on profitability. Botulinum toxin exports to China are in an early shipment phase, and whether volumes continue quarter after quarter is the next point to watch.

In aesthetics, Humedix plans to expand domestic demand through academic marketing, widen distribution for its Elravie cosmetic line and add contract manufacturing orders.

R&D spending is rising: Huons' first-half 2026 R&D was about KRW 21.5 billion on a consolidated basis, equal to 7.44% of sales, and third-quarter R&D rose 13.9% year on year and 21% quarter on quarter.

This cost burden pressures near-term profitability, while the company frames it as investment in drug and vaccine pipelines. For the holding company, earnings depend more on each subsidiary's approval timelines and export restart dates than on broad demand trends.

Comparisons within the sector are therefore more meaningful when they consider operating margins and whether each subsidiary has moved into operating loss, not revenue growth alone.

06

Outlook

The company announced its mid-to-long-term dividend policy in February 2026 and has continued paying quarterly dividends under it.

The third-quarter 2026 dividend has a record date of December 4, 2026 and a scheduled payment date of December 22, 2026, funded through a capital-reserve reduction, which the company said gives shareholders tax-exempt dividend treatment.

The policy also sets out a plan to raise the annual dividend per share step by step.

In the Global business, country-by-country registration and approvals for key products are proceeding as planned, and the company intends to expand sales territories and overseas partnerships in turn as approvals are completed in each country.

It is also pursuing EU GMP and MRI CEP certification to build a base for overseas expansion. Huons plans to establish the vaccine business to broaden its revenue base while continuing R&D investment.

Humedix aims to keep growing through wider distribution of its Elravie cosmetic line and additional contract manufacturing orders. The company's chief executive said the group will keep investing in R&D despite persistent uncertainty and will expand shareholder returns as earnings grow.

The timing of the US export restart and the end of recall-related costs has not been quantified by the company, so the next quarters will show how much of that gap closes.

The next checkpoint is the 2026 annual report, which will carry the fourth-quarter and full-year 2026 figures that are not yet in a periodic report, and such reports are normally filed around late March 2027.

07

Valuation

PER
12.7×
PBR
0.4×
ROE
3.3%
EPS
₩1,477
BPS
₩45,501
Dividend per share
₩880

Market capitalization sits below the parent-attributable equity of KRW 546.7 billion at end-2025, meaning the shares trade under the book value of the equity attributable to parent shareholders. The price-to-book multiple is well below 1x, indicating little premium over net assets.

Because a holding company's share price reflects both the combined value of its subsidiaries and a holding-company discount, earnings swings at core units such as Huons feed directly into how the valuation is read.

Parent-attributable net income over the last four quarters totals KRW 18 billion, less than half of the KRW 38.4 billion recorded in 2023. Earnings-based multiples in this setting depend heavily on how quickly profit recovers, and the roughly halved third-quarter operating profit is a clear example.

Quarterly dividends continue, but they are funded by a capital-reserve reduction, so the dividend capacity should be considered separately from the level of earnings. The central valuation question is how quickly the subsidiaries normalize and whether parent-attributable profit recovers.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Growth in several subsidiaries

Humedix, the aesthetics subsidiary, grew third-quarter 2026 revenue 22.8% year on year to KRW 50.2 billion, with operating profit up 11.3%. The health-supplement unit grew revenue 12.5% to KRW 21.8 billion, and the healthcare-materials unit grew revenue 11.9%.

The botulinum toxin unit's revenue rose 32.8% from the prior quarter on expanded Chinese shipments. Growth across several subsidiaries at once supports the holding company's top line.

Cash generation and a stronger balance sheet

Operating cash flow stayed above KRW 90 billion every year from 2023 through 2025. The debt-to-equity ratio declined from 58.2% in 2022 to 43.0% in 2025. Total equity reached KRW 1.09 trillion at end-2025, including KRW 546.7 billion attributable to parent shareholders, against total liabilities of KRW 468.7 billion. This capital base can act as a financial cushion when subsidiary results fluctuate.

Shareholder returns and net-asset backing

The company published a mid-to-long-term dividend policy in February 2026 and set the third-quarter dividend at a board meeting, with payment scheduled for December 22, 2026. The company said the capital-reserve-funded structure gives shareholders tax-exempt treatment. A price-to-book multiple below 1x is sometimes cited as a downside cushion from a net-asset perspective.

09

Bear factors

Swing to losses at the core subsidiary

Subsidiary Huons posted preliminary third-quarter 2026 revenue of KRW 144 billion, down 6.3% year on year, and an operating loss of KRW 4.5 billion. The end of the continuous glucose monitor business and the absence of US exports drove the revenue decline.

Higher R&D spending, cost increases and recall costs were reflected in the operating loss, which is the main reason consolidated operating profit nearly halved.

Two straight years of operating profit decline

Operating profit peaked at KRW 113.9 billion in 2023, then declined to KRW 97 billion in 2024 and KRW 90.6 billion in 2025. The operating margin fell from 15.0% in 2023 to 10.7% in 2025.

Quarterly operating profit in the first quarter and the third quarter of 2026 both dropped sharply year on year, with the third quarter down 53.9%.

Earnings volatility and cost pressure

Parent-attributable net income swung to a KRW 777 million loss in the second quarter of 2026 and recovered to KRW 6.23 billion in the third quarter, though the third-quarter figure fell 42.2% year on year. Parent-attributable profit over the last four quarters totals KRW 18 billion. Third-quarter R&D spending rose 13.9% year on year and 21% quarter on quarter, adding to the cost burden.

10

Risk factors

Uneven subsidiary performance

The holding company's results depend on the offset between growing units such as Humedix and the health-supplement unit and the operating loss at Huons. If the core subsidiary stays loss-making, growth elsewhere is partly offset at the consolidated operating line.

Because the vaccine business is still establishing its position, the gap may persist until its revenue contribution stabilizes.

Export, approval and recall risk

The absence of US exports and recall costs on an exported product weighed on Huons' profitability. Overseas growth depends on country-by-country approvals, so any delay pushes back the expansion of sales territories. The progress of EU GMP and MRI CEP certification will influence the pace of overseas expansion.

Rising costs and dividend funding

R&D spending has been rising each quarter, with first-half R&D equal to 7.44% of sales. Until this investment produces pipeline results, it may weigh on near-term profitability.

Quarterly dividends are funded by a capital-reserve reduction, so a prolonged earnings decline would raise questions about the sustainability of the dividend policy.

11

What to watch next

  1. December 4, 2026

    Record date for the third-quarter dividend. The shareholder register is fixed on this date, and it is the starting point for checking whether the mid-to-long-term dividend policy is carried out.

  2. December 22, 2026

    Scheduled payment date for the third-quarter dividend. Whether payment proceeds on schedule is the factual test of the shareholder-return policy.

  3. Late January 2027

    Expected timing for the preliminary fourth-quarter and full-year 2026 results. The check is whether Huons' operating loss and the vaccine revenue contribution show up in the fourth quarter.

  4. Late March 2027

    Expected filing period for the 2026 annual report. The fourth-quarter and full-year 2026 confirmed results, the annual dividend outcome and the annual operating margin will first appear in a periodic report here.

  5. Around May 15, 2027

    Around the filing deadline for the first-quarter 2027 report. The check is whether the US export restart and the end of recall costs appear in revenue and operating profit.

12

Overall view

Huons Global's third-quarter 2026 revenue reached KRW 214.8 billion, up 1.7% year on year, while operating profit fell 53.9% to KRW 9.39 billion, a period in which top-line growth and weaker profitability appeared together.

On an annual basis, revenue grew for three consecutive years from 2023 through 2025, but operating profit declined for two consecutive years from 2024, and the operating margin fell from 15.0% in 2023 to 10.7% in 2025.

The core subsidiary Huons swung to a preliminary third-quarter operating loss of KRW 4.5 billion, and growing subsidiaries such as Humedix and the health-supplement unit offset part of that drag.

On the financial side, the debt-to-equity ratio fell to 43.0% in 2025 and operating cash flow stayed above KRW 90 billion each year, giving a thick financial cushion.

A price-to-book multiple well below 1x is a factual asset-side comparison, but it should be read alongside parent-attributable profit of KRW 18 billion over the last four quarters.

The next checkpoints are the December 4, 2026 record date and December 22, 2026 payment date for the dividend, and the 2026 annual report that will carry fourth-quarter and full-year figures. The timing of Huons' US export restart and the contribution from the vaccine business are the key variables for this report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. fintechtimes.co.kr
  2. news.jkn.co.kr
  3. ziksir.com
  4. insightkorea.co.kr
  5. m.sedaily.com
  6. pharmnews.com
  7. medicaldaily.co.kr
  8. supple.kr
  9. todaymild.com
  10. thebionews.net
  11. fntimes.com
  12. biztribune.co.kr
  13. comp.fnguide.com
  14. thefairnews.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis